Abstract:Coronaviruses are a major healthcare threat to humankind. Currently, the host factors that contribute to limit disease severity in healthy young patients are not well defined. Interferons are key antiviral molecules, especially type I and type III interferons. The role of these interferons during coronavirus disease is a subject of debate. Here using mice that are deficient in type I (IFNAR1 -/- ), type III (IFNLR1 -/- ) or both (IFNAR1/LR1 -/- ) interferon signaling pathways and murine adapted coronavirus (MHV-A59) administered through intranasal route, we define the role of interferons in coronavirus infection. We show that type I interferons play a major role in host survival in this model while a minimal role of type III interferons was manifested only in the absence of type I interferons or during a lethal dose of coronavirus. IFNAR1 -/- and IFNAR1/LR1 -/- mice had an uncontrolled viral burden in the airways and lung and increased viral dissemination to other organs. The absence of only type III interferon signaling had no measurable difference in the viral load. The increased viral load in IFNAR1 -/- and IFNAR1/LR1 -/- mice was associated with increased tissue injury, especially evident in the lung and liver. Type I but not type III interferon treatment was able to promote survival if treated during early disease. Further, we show that type I interferon signaling in macrophages contributes to the beneficial effects during coronavirus infection in mice. Importance: The antiviral and pathological potential of type I and type III interferons during coronavirus infection remains poorly defined and opposite findings have been reported. We report that both type I and type III interferons have anti-coronaviral activities, but their potency and organ specificity differ. Type I interferons deficiency rendered the mice susceptible to even a sublethal murine coronavirus infection, while the type III interferon deficiency impaired survival only during a lethal infection or during a sublethal infection in absence of type I interferon signaling. While treatment with both type I and III interferons promoted viral clearance in the airways and lung, only type I interferons promoted the viral clearance in the liver and improved host survival upon early treatment (12 hours post infection). This study demonstrates distinct roles and potency of type I and type III interferons and their therapeutic potential during coronavirus lung infection.

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

Efficacy of molnupiravir and interferon for the treatment of SARS‐CoV‐2 in golden Syrian hamster

Interferon‐α‐2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease‐2019

Prior Influenza Infection Mitigates SARS-CoV-2 Disease in Syrian Hamsters

Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters

Evaluating the Protective Role of Intranasally Administered Avian-Derived IgY Against SARS-CoV-2 in Syrian Hamster Models

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

The role of type I interferon in the treatment of COVID‐19

Interferon-α2b Spray Inhalation Did Not Shorten Virus Shedding Time of SARS-CoV-2 in Hospitalized Patients: a Preliminary Matched Case-Control Study

Type I interferons and SARS-CoV-2: from cells to organisms

Differential Interferon-Α Subtype Induced Immune Signatures Are Associated with Suppression of SARS-CoV-2 Infection.

Early corticosteroid treatment enhances recovery from SARS-CoV-2 induced loss of smell in hamster

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Relative Timing of Type I Interferon Response and Virus Replication Determines Disease Outcome During Respiratory Virus Infection

Distinct Roles of Type I and Type III Interferons During a Native Murine β Coronavirus Lung Infection

STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

A Recombinant Humanized Monoclonal Antibody to Venezuelan Equine Encephalitis Virus E2 That Neutralizes Virus in Vitro and is Effective Prophylactically in Vivo

Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model

Full-Lung Prophylaxis Against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients